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Abstract
Treatment of carbapenemase-producing Enterobacterales bloodstream infections (CPE-BSI) in 
solid-organ transplant recipients (SOT) is challenging. The objective of this study was to develop 
a specific score to predict mortality in SOT recipients with CPE-BSI. A multinational, 
retrospective (2004-2016) cohort study (INCREMENT-SOT, ClinicalTrials.gov NCT02852902) 
was performed. The main outcome variable was 30-day all-cause mortality. The INCREMENT-
SOT-CPE score was developed using logistic regression. The global cohort included 216 patients. 
The final logistic regression model included the following variables: INCREMENT-CPE mortality 
score ≥8 (8 points), no source control (3 points), inappropriate empirical therapy (2 points), 
cytomegalovirus disease (7 points), lymphopenia (4 points), and the interaction between 
INCREMENT-CPE score ≥8 and CMV disease (minus 7 points). This score showed an area under 
the receiver operating characteristic curve of 0.82 (95% CI 0.76-0.88) and classified patients into 
three strata: 0–7 (low mortality), 8-11 (high mortality) and 12-17 (very-high mortality). We 
performed a stratified analysis of the effect of monotherapy versus combination therapy among 
165 patients who received appropriate therapy. Monotherapy was associated with higher mortality 
only in the very-high (adjusted HR 2.82, 95% CI 1.13-7.06, P=0.03) and high (HR 9.93, 95% CI 
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1. Introduction
Infections due to carbapenemase-producing Enterobacterales (CPE) are dramatically increasing 
worldwide [1]. Numerous transplant centres have been affected by outbreaks and many suffer a 
subsequent endemic situation [2–4]. The extreme difficulty for their treatment and the high 
mortality (30-50%) associated with these infections explain their importance in the solid-organ 
transplant (SOT) setting [4,5]. Their epidemiology has been extensively studied and specific 
recommendations for infection control and clinical management of these infections in SOT 
recipients have been published [4–8]. Nevertheless, current recommendations are based on 
observational studies conducted in the general population [9–13], while the specific risk factors 
and clinical impact of infections due to CPE in SOT recipients remains to be elucidated. Large, 
multicenter studies, truly representative of the SOT patient population, are needed to develop risk-
stratification tools to assist in guiding the management of these infections. 
The objectives of this study were: (I) to validate the INCREMENT-CPE score to predict all-cause 
mortality of CPE bloodstream infections (CPE-BSI) in the SOT population; (II) to explore if a 
new predictive score, INCREMENT-SOT CPE score, improves the predictive capacity, and (III) 
to check the utility of the new score to guide antibiotic therapy (monotherapy or combination) in 
different mortality risk groups. 
2. Methods
2.1.  Study design and population
This report follows STROBE recommendations [14] (Supplementary Table S1). We conducted a 
retrospective (2004-2016), international (40 SOT centres in 16 countries) cohort study of 
consecutive cases of adult SOT recipients with clinically significant, monomicrobial bloodstream 
infections by carbapenemase and/or extended spectrum-β-lactamase-producing Enterobacterales 
(INCREMENT-SOT Project; ClinicalTrials.gov identifier NCT02852902). In this work, we 
present the analysis of the CPE-BSI episodes from this cohort, which were submitted by 26 
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the Spanish Agency for Medicines and Health Products (AEMPS, code FIB-COL-2015-01) and by 
the Hospital Universitario Reina Sofia Ethics Committee (code 2907). Exclusion criteria were 
unavailability of key data and death within 48 hours after the blood cultures were obtained. 
2.2. Variables and definitions
Clinically significant BSI was defined as the isolation of a carbapenemase-producing 
Enterobacterales in blood [16]. Episodes were considered nosocomial if symptoms started later 
than 48 hours after hospital admission or within 48 hours of a previous hospital discharge. The 
main outcome variable was 30-day all-cause mortality. Independent variables included 
demographics and variables related to comorbidities: Charlson comorbidity index score [17], 
diabetes, chronic pulmonary disease, kidney disease, and McCabe classification, according to 
three categories: non-fatal (mild and only a few comorbidities), ultimately fatal (risk of death 
within four years or multiple comorbidities) and rapidly fatal (risk of death during stay, intensive 
or terminal care patients). SOT-related variables included time from transplant to bloodstream 
infection, basal and induction immunosuppression, and transplanted organ. Variables recorded in 
the 30 days previous to the BSI episode were: stay in an Intensive Care Unit (ICU), dialysis, acute 
rejection of the transplanted organ, cytomegalovirus (CMV) replication (any level of DNAemia), 
and CMV disease (presence of symptoms with evidence of CMV infection, including viral 
syndrome and organ disease), and trimethoprim/sulfamethoxazole prophylaxis. Variables recorded 
at the time of BSI onset included urinary stenosis (kidney), biliary stenosis (liver) and traqueal 
stenosis (lung), severity of acute condition at presentation according to Pitt bacteraemia score [18], 
severity of systemic inflammatory response syndrome on day 0 (blood culture date) [19], mental 
status (four categories: alert, disoriented, stuporeous and comatose), lymphocyte csource of 
infection according to clinical and microbiological data, source control and use of mechanical 
ventilation. Microbiological variables included Enterobacterales species, carbapenemase type, 
antimicrobial susceptibility data. Finally, we recorded INCREMENT-CPE mortality risk score 
[11,12] and the therapy administered (dates and doses of antibiotics). Empirical therapy was 
considered appropriate when an active drug was administered before the susceptibility profile. 
Targeted therapy was considered appropriate if it included an active drug and was administered 
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available. An active therapy was classified as monotherapy if included one single active drug and 
as combined therapy if included 2 or more active drugs. If the antibiotic regimen administered was 
changed, we considered that administered for ≥50% of the duration of therapy (for patients who 
died sooner than 48 hours after the start of therapy, one complete day of therapy was required). 
Meropenem and imipenem were considered active when MIC < 4mg/L (monotherapy) or MIC 8-
16 mg/L and administered in combination with ertapenem (monotherapy) or other active drugs 
(combination therapy). Tigecycline was not considered active for urinary source. Variables were 
collected in a centralized electronic clinical research file. The database was curated and queries 
were sent to participating centres for missing or inconsistent data.
2.3.  Microbiological studies
The identification of microorganisms and susceptibility testing were performed at each 
participating centre. The identification of microorganisms and susceptibility testing were 
performed at each participating center, using standard microbiological techniques. Susceptibility 
was studied using automated systems or disk diffusion at each local laboratory and interpreted 
using the 2015 CLSI break points [17]. For isolates obtained before 2015, minimum inhibitory 
concentrations (MICs) were reviewed and the susceptibility category was assigned accordingly; 
when the MIC was not available or the available data had a MIC less than or equal to the older 
susceptibility break point, these were considered as susceptible if so reported by the local 
laboratory. Isolates were considered to be carbapenemase producers if a carbapenemase gene was 
detected by a molecular method.
2.4.  Statistical procedures
Continuous variables were compared using the Kruskal-Wallis test. Categorical variables were 
compared using the chi-squared test or Fisher’s exact tests. Survival distributions were compared 










This article is protected by copyright. All rights reserved
Validation of the INCREMENT-CPE score [12]  was performed by calculating the area under the 
receiver operating characteristic curve (AUROC) for observed data, the sensitivity (Se) and 
specificity (Sp). 
Multivariable logistic regression was used to develop a new score. The original INCREMENT-
CPE score (modified by excluding the variable “inappropriate empirical and early targeted 
therapy”, since we aimed to investigate different aspects of treatment for the new score) was 
dichotomized into two previously validated categories of risk (<8, low-risk versus ≥8, high-risk) 
[11]. To control for the site effect, we classified centres into low-mortality-risk and high-
mortality-risk using TreeNet (Salford Predictive Modeller software) and considering all other 
variables (Supplementary Figure S1). The study period (to control for changes in clinical 
management over time), the source of BSI and lymphocyte count were dichotomized by CART 
(Classification and Regression Tree, Salford Predictive Modeller Software; Supplementary 
Table S2 and Supplementary Figure S2). The variance inflation factor (VIF) value for every 
variable was calculated to control the influence of multicollinearity. We assumed lack of 
multicollinearity if all variables had a VIF value <2. The variable “high-mortality risk centre” was 
included in the analysis to obtain a predictive model for which this effect was controlled but was 
not considered for the score. Potential interactions between variables were explored using TreeNet 
and those selected were included in the models. Variables with a P ≤ 0.20 in the final models were 
selected for the assignment of a score provided their inclusion significantly improved the 
predictive capacity of the model. A weighted score for each variable was calculated dividing each 
regression coefficient by one-half of the smallest coefficient and rounding to the nearest integer. 
The prediction ability of a model was examined by calculating its AUROC with a 95% confidence 
interval; Se, Sp, positive predictive value (PPV), negative predictive value (NVP) and accuracy 
(Ac) were calculated for different breakpoints. 
Sensitivity analysis for the INCREMENT-SOT-CPE score was performed using Salford 
Predictive Modeller Software to check the robustness of its predictive ability. Fifteen subgroups of 
the cohort with a 20% sample size were randomly extracted (43 cases per subgroup), and the 
AUROC of the score to predict 30-day all-cause mortality was calculated for each subgroup. A 
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another 7 times, extracting 15 subgroups with sample sizes ranging 30% to 90% (10% intervals, 
thus obtaining 8 average AUROCs, maximum, and minimum values).
For the analysis of the association of monotherapy versus combination therapy with mortality, a 
propensity score for receiving combination therapy was calculated using a non-parsimonious 
logistic regression model. The impact of combination therapy was studied by Cox-regression, 
adjusting by propensity score and other potential confounders, after checking for collinearity. 
The analyses were carried out using R software (version 3.0.1), SPSS 25.0 (SPSS Inc.), and 
Salford Predictive Modeller software 8.2 (includes CART and TreeNet). 
3. Results
3.1.  Cohort features and validation of the INCREMENT-CPE mortality score 
(objective I).
Among 228 patients included, 216 fulfilled inclusion criteria (Figure 1). Their characteristics are 
shown in Table 1. Most patients were men (75%), with a median (interquartile range) age of 56 
(46-63). The most common types of transplant were liver (56%, including liver-other organs) and 
kidney (35%, including kidney-pancreas). Episodes occurred in the first month post-transplant in 
45% of patients. The most common basal immunosuppression regimes included tacrolimus (85%), 
mycophenolic acid/mycophenolate (58%), and corticosteroids (83%). 43% of patients received 
induction of immunosuppression with thymoglobulin (21%) or basiliximab (22%). In the previous 
30 days, 24% suffered CMV replication and 8% CMV disease. Lymphopenia was observed in 
47% of cases. The most common sources of bloodstream infections were intrabdominal (21%), 
urinary tract (20%), biliary tract (18%), catheters (13%), and lung (10%). The most common 
organism involved was Klebsiella pneumoniae (83%) and the most common types of 
carbapenemases were KPC (66%) and OXA-48 (23%). Regarding treatment regimens, 
inappropriate empirical therapy was administered in 21% (45/216) of patients and appropriate 
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patients). 30-day all-cause mortality was 37% (79/216; 95% CI, 31%-43%). Significant 
differences between types of SOT were observed in a number of variables, including Charlson 
index, chronic pulmonary disease, kidney disease, McCabe score, CMV replication, induction of 
immunosuppression, urinary and biliary stenosis, Pitt score, source of infection, administration of 
appropriate empirical therapy, and INCREMENT-CPE score (Table 1).
The predictive value of the INCREMENT-CPE mortality score [12] was studied. We found that 
this score was associated with 30-day all-cause mortality (OR, 1.40 per unit; 95% CI, 1.27-1.56; 
P<0.001), showing an AUROC of 0.78 (95% CI, 0.71-0.85). The Se, Sp, PPV, NPV and Ac 
values for different breakpoints of each INCREMENT-CPE score and the proportion of patients 
are shown in Supplementary Table S3. For an INCREMENT-CPE score value ≥8, previously 
validated as a cut-off value predictive for low versus high mortality in non-SOT patients [11,12], 
the calculated NPV and PPV in the SOT cohort were 84.7% and 50.4%, respectively.
3.2.  Development of the new INCREMENT-SOT-CPE mortality score (objective 
II).
We explored SOT-related variables that could improve the predictive capacity of the 
INCREMENT-CPE score in our population. Variables associated with 30-day mortality in the 
final model were: INCREMENT-CPE score ≥8 (excluding the variable about therapy from this 
score), CMV disease in the previous 30-days, lymphocytes ≤600 units per mm3, and lack of source 
control (Table 2); the interaction between CMV disease and INCREMENT-CPE score ≥8 was 
negative and with a similar (but negative) β coefficient as CMV disease, indicating that CMV 
disease does not further increase the risk of death if the INCREMENT-CPE-score is ≥8, but do so 
only if the score is <8 (Supplementary Figure S3). The variable inappropriate empirical therapy 
was kept in the final model since its inclusion improved the predictive capacity. None of the final 
variables included in the multivariate model showed multicollinearity (VIF ≤ 1.06, 
Supplementary Table S4). The AUROC of the resulting logistic regression model was 0.84 (95% 
CI, 0.78-0.89). The score assigned to each variable according to its beta regression coefficient is 
shown in Table 3. The prediction rule based on the scores showed an AUROC of 0.82 (95% CI, 
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INCREMENT-CPE score (previous section, objective I). We also developed an alternative model 
including variables independently of the INCREMENT-CPE score, nevertheless the resulting 
model showed a lower predictive capacity than our INCREMENT-CPE score-based model 
(AUROC=0.79, 95% CI 0.73-0.85).
The sensitivity, specificity positive predictive value (PPV), negative predictive value (NPV) and 
accuracy for different breakpoints of the new INCREMENT-SOT-CPE score and the proportion 
of patients are shown in Supplementary Table S5. The NPV and PPV for a score value ≥8 were 
89.4% and 53.4%, respectively; and for a score ≥12, NPV and PPV were 78.8% and 72.3%, 
respectively. A classification into low (score 0-7), high (score 8-11), and very-high (score 12-17) 
mortality was developed, with mortality rates of 11.4% (10/87), 35.3% (23/65) and 71.8% (46/64), 
respectively (Supplementary Table S6). The sensitivity analysis (see Methods for details) 
confirmed the robustness of the model; the minimum value of the AUROCs for all subcohorts was 
always >0.70 and the average AUROC value >0.80 (Supplementary Figure S4). 
3.3.  Utility of the new score to guide antibiotic therapy. Impact of monotherapy 
versus combined therapy on 30-day all-cause mortality (objective III). 
We analysed 165 patients who received appropriate targeted treatment (treatment cohort, Figure 
1). Thirty-day all-cause mortality was 15.7% (11/70) in patients receiving combined therapy 
versus 43.1% (41/95, P<0.001) in patients receiving monotherapy. Mortality associated with each 
type of treatment in the different mortality risk groups, as defined by INCREMENT-SOT-CPE 
score, is shown in Supplementary Table S7. In a COX-regression model adjusted by the 
propensity score for receiving combination therapy, INCREMENT-SOT-CPE score and high-
mortality risk centre, monotherapy was associated with higher mortality in the global cohort (HR 
3.68; 95% CI, 1.83-7.40; P<0.001) and in the two higher INCREMENT-SOT-CPE mortality risk 
strata, i.e. very-high risk  (adjusted HR 2.82, 95% CI, 1.13-7.06, P=0.03) and high risk  (adjusted 
HR 9.93, 95% CI, 2.08-47.40, P=0.004] (Table 4). By contrast, in the low risk stratum, no 
significant differences were observed (adjusted HR 1.69, 95% CI, 0.32-8.89, P=0.54) (Table 4). 
Kaplan Meier curves are shown in Supplementary Figure S5. The specific antimicrobials 
administered to patients in the three INCREMENT-SOT-CPE risk groups were heterogeneous and 
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3.4.  Proposed algorithm for clinical practice
In order to apply these results to the clinical management of SOT patients with CPE-BSI, we 
propose an algorithm which requires calculation of INCREMENT-CPE score [11,12] and 
identification of the number and type of risk factors present, without having to expressly calculate 
the new score (Figure 2). According to this algorithm, 86/165 (52.1%) patients in the therapy 
cohort received inadequate antibiotic therapy. Specifically, 57/165 (34.5%) of the patients who 
received monotherapy should have been treated with combined therapy. These patients had a 30-
day mortality rate of 53.4% (31/57). On the other side, 29/165 (17.6%) of the patients who 
received combined therapy should have received monotherapy. The mortality rate in this second 
group was 3.8% (2/29). An expanded version of the algorithm, including the stratification of the 
risk of mortality, based on the INCREMENT-SOT score, is provided in Supplementary Figure 
S6. 
4. Discussion
Our results indicate that being a recipient of SOT does not seem to worsen the prognosis of 
CPE-BSI. Thirty-day all-cause mortality in our INCREMENT-SOT cohort was 36.6%, higher that 
in pre-CPE era [15] and similar that previously reported in other series in SOT [4], and in the 
general population. [12]. Some studies and a meta-analysis have reported a higher mortality 
(>40%) when CPE-BSI is caused by K. pneumoniae. In our study, the type of Enterobacterales 
was not associated with mortality in the analysis after adjusting by other exposures, as previously 
observed [16–18]. 
The development of new INCREMENT-SOT-CPE score was based on the INCREMENT-
CPE score, which had been previously validated in the general population in different studies 
[9,11,12,19,20]. We used this strategy because there are no specific studies in SOT and many 
transplant groups use this predictive model, which takes into account variables important in any 
type of patient with BSI, including SOT. Besides, the inclusion of this general model in our new 
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period, when the full impact of immunosuppression -derived from prolonged exposure to 
suppressive therapies- is still absent [21]. Finally, an alternative model including individual 
variables –transplant and non-transplant-, instead of the INCREMENT-CPE score, showed a 
lower predictive capacity and was thus not considered.
We additionally studied the impact of specific transplant variables that complemented the 
INCREMENT-CPE score on the prognosis of this type of infections in SOT-patients. So, our 
results indicate that the predictive capacity of INCREMENT-CPE score can be improved when it 
is combined with other mortality predictors such as source control, appropriate empirical therapy 
and variables related to immunosuppression, i.e. lymphopenia and CMV disease. The application 
of these additional predictors is very important in patients with INCREMENT-CPE score <8, 
when the score can be applied to indicate monotherapy or combined therapy (Figure 2). 
It is obvious that an adequate control of the source and an appropriate empirical treatment can 
improve the prognosis of the bacterial infection. Lymphopenia can be a surrogate marker of over-
immunosuppression. Nevertheless, some experts believe that a reduction in immunosuppression 
may lead to higher mortality by increasing the capacity of the immune system to induce a systemic 
inflammatory response [22].
CMV is an immunomodulatory virus that can favour bacterial infections [23]. Theoretically, CMV 
prevention could reduce this increased risk [24], although recent consensus do not recommend 
CMV prophylaxis is the scenario of solid-organ transplantation  [23,25]. This is further 
complicated by the fact that sepsis may increase CMV reactivation [25,26]. Our results suggest 
that CMV disease increase mortality in SOT recipients with CPE-BSI, although CMV disease may 
also be a mere marker of the net-state of over-immunosuppression, which would be ultimately 
associated with all-cause mortality. Interestingly, the data from our study suggest that CMV 
disease does not increase the risk of death further in SOT recipients with a high underlying risk of 
death, as measured by the INCREMENT-CPE score, but only in patients with a lower underlying 
risk. Unfortunately, data on CMV prophylaxis was not collected in this study, but our results open 
the door to further research about whether prevention of CMV may be beneficial in SOT 
recipients colonized by CPE in order to improve their outcomes in case of an invasive infection 
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Our study has the limitations of retrospective studies, despite applying a rigorous definitions and 
statistical analyses to control biases. A second limitation is that we have analysed patients not 
treated with the newly available drugs (i.e. ceftazidime-avibactam or meropenem-vaborbactam). 
The impact of the new drugs on the applicability of risk scores to decision making will certainly 
need to be investigated, as it is not known if combination therapy would be needed in high-risk 
patients when the newer drugs are used, or if the new drugs are more effective in low-risk patients. 
However, it is important to bear in mind that accessibility to the new drugs is still limited in 
numerous countries, and therefore well-conducted observational studies in the SOT population 
treated with the “classic” drugs will still be relevant in many areas. Another limitation is that the 
sample size of our cohort precluded the selection of derivation and validation subcohorts (see 
[12]). The sensitivity analysis confirmed the internal robustness of our model, nevertheless, an 
external validation in a prospective cohort would be desirable. Finally, KPC carbapenemase may 
be overrepresented in our cohort, as compared to other carbapenemases. 
To conclude, in transplant centers with outbreaks or endemia by CPE, identification of colonized 
patients is important so that empirical treatment with CPE coverage can be readily administered in 
case of BSI development. In this study, we have identified transplant-related variables specifically 
associated with the risk of mortality in SOT recipients with CPE-BSI. We expect this will help to 
identify patients at high risk of death and allow a more personalized clinical management, i.e. 
prevention of cytomegalovirus disease and the judicious use of immunosuppression in order to 
avoid lymphopenia.
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Figure Legends
Figure 1. Flow-chart of analysed solid-organ transplant patients with bloodstream infections due 
to carbapenemase-producing Enterobacterales.
Figure 2. Algorithm for clinical management of SOT patients with bloodstream infection due to 
carbapenemase-producing Enterobacterales (CPE-BSI), based on INCREMENT-SOT-CPE 
mortality risk score.
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 Tables 
Table 1. Characteristics of solid-organ transplant patients with bloodstream infections 
caused by carbapenemase–producing Enterobacterales included in the INCREMENT-
SOT cohort, according to the transplanted organ.  
   Transplanted solid organ   













Age, median (IQR) 56 (46-63) 55 (46-63) 57 (46-64) 56 (40-60) 48 (35-62) 62 (52) 0.58b 
Gender (Male) 162 (75) 92 (77) 56 (75) 8 (62) 4 (67) 2 (100) 0.68 
Charlson index, median (IQR) 5 (3-7) 5 (4-7) 5 (3-6) 4 (5-7) 2 (1-5) 6 (5) 0.01b 
Diabetes 87 (40) 46 (38) 35 (47) 4 (31) 2 (33) 0 0.49 
Chronic pulmonary disease 15 (7) 3 (3) 6 (8) 1 (8) 5 (83) 0 <0.001 
Kidney disease 120 (56) 37 (33) 64 (85) 8 (62) 1 (17) 2 (100) <0.001 
McCabe score             <0.001 
Non-Fatal Disease 53 (25) 22 (18) 25 (33) 5 (39) 1 (17) 0 .. 
Rapidly Fatal Disease 47 (22) 36 (30) 4 (5) 6 (46) 1 (17) 0 .. 
Ultimately Fatal Disease 115 (53) 61 (51) 46 (61) 2 (15) 4 (67) 2 (100) .. 
Days from transplant to bloodstream 
infection 
            0.10 
≤30 days 97 (45) 63 (53) 24 (32) 6 (46) 3 (50) 1 (50) .. 
31-180 days 75 (35) 37 (31) 32 (43) 5 (39) 0 1 (50) .. 
≥ 181 days 44 (20) 20 (17) 19 (25) 2 (15) 3 (50) 0 .. 
Basal immunosuppression               
Cyclosporine 17 (8) 5 (4) 8 (11) 3 (23) 1 (17) 0 0.09 
Tacrolimus 183 (85) 109 (91) 60 (80) 8 (62) 4 (67) 1 (50) 0.01 
Mycophenolic acid/  
125 (58) 54 (45) 57 (76) 10 (77) 2 (33) 2 (100) <0.001 
Mycophenolate 
Corticosteroids 180 (83) 90 (75) 69 (92) 13 (100) 6 (100) 2 (100) 0.006 
Azathioprine 6 (3) 0 3 (4) 1 (8) 2 (33) 0 <0.001 
Everolimus 11 (5) 7 (6) 3 (4) 0 1 (17) 0 0.49c 
Sirolimus 2 (1) 1 (1) 1 (1) 0 0 0 1c 
Induction of immunosuppression 92 (43) 26 (22) 55 (73) 5 (39) 5 (83) 1 (50) <0.001 
Thymoglobulin 46 (21) 6 (5) 36 (48) 2 (15) 2 (33) 0 <0.001 
Basiliximab 47 (22) 20 (17) 20 (27) 3 (23) 3 (50) 1 (50) 0.16 
Nosocomial acquisition 180 (83) 102 (85) 57 (76) 13 (100) 6 (100) 2 (100) 0.12 
ICU stay (previous 30 days) 149 (69) 92 (77) 37 (49) 12 (92) 6 (100) 2 (100) <0.001 
Dialysis (previous 30 days) 79 (36) 37 (31) 31 (41) 8 (62) 2 (33) 1 (50) <0.001 
Acute rejection (previous 30 days) 21 (10) 7 (6) 8 (11) 5 (39) 1 (17) 0 0.005 
CMV disease (previous 30 days) 17 (8) 7 (6) 7 (9) 3 (23) 0 0 0.22 
CMV replication (previous 30 days) 52 (24) 30 (25) 13 (17) 9 (69) 0 0 <0.001 
TMP/SMX prophylaxis (previous 30 
days) 
119 (55) 62 (52) 43 (57.3) 8 (61.5) 4 (66.7) 2 (100) 0.58 
Urinary stenosis (kidney) 11 (5) 0 11 (15) 0 0 0 <0.001c 
Biliary stenosis (liver) 33 (15) 33 (28) 0 0 0 0 <0.001 
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Pitt score   3 (1-6) 4 (1-6) 1 (0-4) 6 (2-11) 5 (3-9) 3 <0.001b 
Systemic inflammatory response 
syndrome 
            0.004 
Sepsis 99 (46) 47 (39) 45 (60) 4 (31) 3 (50) 0 .. 
Severe sepsis 54 (25) 36 (30) 9 (12) 3 (23) 3 (50) 2 (100) .. 
Shock 63 (29) 37 (31) 21 (28) 6 (46) 0 0 .. 
Mental status              0.02 
Alert 81 (38) 36 (30) 40 (53) 4 (31) 1 (17) 0 .. 
Disoriented 58 (27) 34 (28) 17 (21) 2 (15) 3 (50) 2 (100) .. 
Stuporeous 31 (14) 20 (17) 7 (9) 3 (23) 1 (17) 0 .. 
Comatose 35 (16) 24 (20) 6 (8) 4 (31) 1 (17) 0 .. 
Lymphocytes <600/mm3 101 (47) 56 (47) 35 (47) 7 (54) 3 (50) 0 0.73 
Source of infection             <0.001 
Intrabdominal 46 (21) 36 (30) 8 (11) 1 (8) 0 1 (50) .. 
Urinary tract 44 (20) 4 (3) 39 (52) 1 (8) 0 0 .. 
Biliary tract 38 (18) 38 (32) 0 0 0 0 .. 
Vascular access 28 (13) 12 (10) 12 (16) 4 (31) 0 0 .. 
Pneumonia 21 (10) 6 (5) 6 (8) 3 (23) 6 (100) 0 .. 
Skin and soft tissue 5 (2) 0 4 (5) 0 0 1 (50) .. 
Other 16 (7) 15 (13) 1 (1) 0 0 0 .. 
Unknown 18 (8) 9 (8) 5 (7) 4 (31) 0 0 .. 
No source control 55 (26) 29 (24) 23 (31) 1 (8) 2 (33) 0 0.38 
Mechanical ventilation 92 (43) 57 (48) 20 (27) 9 (69) 5 (83) 0 0.001 
Enterobacterales             0.05 
Klebsiella sp. 180 (83) 99 (83) 64 (86) 11 (85) 5 (83) 1 (50) .. 
Enterobacter sp. 16 (7) 8 (7) 6 (8) 1 (8) 0 0 .. 
Escherichia coli 15 (7) 10 (8.3) 4 (5) 0 1 (17) 0 .. 
Morganella morganii 1 (0.5) 1 (1) 0 0 0 0 .. 
Serratia sp. 4 (2) 2 (2) 1 (1) 1 (8) 0 1 (50) .. 
Type of carbapenemase             0.29 
KPC 143 (66) 79 (66) 51 (68) 8 (62) 4 (67) 1 (50) .. 
OXA-48 50 (23) 31 (26) 15 (20) 4 (31) 0 0 .. 
Other  23 (11) 10 (8) 9 (12) 1 (8) 2 (33) 1 (50) .. 
INCREMENT-CPE scorea, median 
(IQR) 
8 (6-12) 11 (6-12) 6 (3-11) 13 (7-15) 11 (4-15) 11 (11-11) 0.005b 
Inappropriate empirical therapy 45 (21) 24 (20) 18 (24) 2 (15) 1 (17) 0 0.86 
Targeted therapy             0.64 
Appropriate monotherapy 118 (55) 66 (55) 44(59) 5 (39) 3 (50) 0 .. 
Appropriate combination therapy 72 (33) 39 (33) 23 (31) 6 (46) 2 (33) 2 (100) .. 
Inappropriate  26 (12) 15 (13) 8 (11) 2 (15) 1 (17) 0 .. 
Cure/Improvement at day 14 122 (57) 67 (56) 47 (63) 4 (31) 2 (33) 2 (100) 0.11 
Mortality at day 30 79 (37) 47 (39) 21 (28) 8 (65) 3 (50) 0 0.10 
 
Data are number of patients (percentage), except where specified. P values represent global differences among 
the five types of solid organ transplant and were obtained by Chi-squared test, except when otherwise stated. a 
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bacteraemia score ≥6 (4 points), Charlson index ≥2 (3 points), source of BSI other than urinary or biliary tracts 
(3 points) and receiving inappropriate empirical and early targeted therapy (2 points).b Kruskall-wallis test. c 
Fisher´s test. Abbreviations: IQR, interquartile range; ICU, intensive care unit; CMV, cytomegalovirus; 
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Table 2. Multivariate logistic regression analysis of variables associated with 30-day all-
cause mortality. 
 Crude analysis Adjusted analysis
b,c 
Variable OR (95% CI) p value OR (95% CI) p value 
Age (per unit)  0.99 (0.97-1.01) 0.36 .. .. 
Male gender 1.08 (0.57-2.09) 0.81 .. .. 
Klebsiella sp. 1.77 (0.83-4.04) 0.15 .. .. 
Carbapenemase   .. .. 
Carbapenemase Reference    
Carbapenemase +ESBL 0.71 (0.35-1.42) 0.33 .. .. 
OXA-type carbapenemase 1.07 (0.56- 2.01) 0.84 .. .. 
Nosocomial acquisition 1.61 (0.75- 3.70) 0.23 .. .. 
ICU admission 4.92 (2.42-10.89) <0.0001 .. .. 
Mechanical ventilation 7.48 (4.04-14.30) <0.0001 .. .. 
Mental status, not alert 17.6 (6.80-51.18) <0.0001 .. .. 
Chronic kidney disease 1.01 (0.58-1.77) 0.97 .. .. 
Chronic pulmonary disease 2.09 (0.72-6.19) 0.17 .. .. 
Severe liver disease 1.70 (0.92-3.15) 0.09 .. .. 
Any tumor 1.51 (0.61-3.68) 0.36 .. .. 
Charlson index, per unit 1.08 (0.95-1.22) 0.20 .. .. 
Pitt Score, per unit 1.55 (1.38-1.75) <0.0001 .. .. 
Septic Shock 8.68 (0.46-16.90) <0.0001 .. .. 
Days from transplant to positive blood culture     
≤30 days Reference    
31-180 days 0.46 (0.24-0.90) 0.02 .. .. 
≥ 181 days 1.04 (0.51-2.13) 0.92 .. .. 
Type of SOT     
Kidney (including kidney-pancreas) Reference    
Liver including (liver-kidney,  
liver-pancreas and multivisceral) 
1.61 (0.87-3.00) 0.13 .. .. 
Others (lung and heart) 3.54 (1.25-10.01) 0.17 .. .. 
Source of infection in SOT     
High risk (pneumonia and others) Reference    
Low risk (rest of sources) 0.36 (0.17-0.75) 0.006 .. .. 
Biliary stenosis 0.84 (0.37-1.82) 0.67 .. .. 
Previous dialysis 1.33 (0.75-2.36) 0.33 .. .. 
INCREMENT-CPE mortality score ≥8
 a
 6.72 (3.52-13.55) <0.0001 13.74 (6.00-35.07) <0.0001 
CMV disease within 30 days before HC 2.69 (1.00-7.71) 0.05 10.87 (1.79-77.06) 0.01 
Lymphocytes ≤600 units/mm3 0.96 (0.91-0.99) 0.03 3.46 (1.73-7.16) 0.0006 
No source control  2.00 (1.09-3.85) 0.03 2.66 (1.18-6.22) 0.02 
Inappropriate empirical therapy  1.92 (0.99-3.70) 0.06 1.89 (0.77-4.26) 0.18 
High-mortality risk centre 3.10 (1.75-5.56) 0.0001 3.72 (1.83-7.82) 0.0004 
Study period 2007-2010 (reference: 2011-2016) 1.91 (0.87-4.17) 0.10 .. .. 
Interaction INCREMENT-CPE mortality score 
≥8 x CMV disease 
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a The INCREMENT-CPE mortality score included the following variables: severe sepsis or shock at 
presentation (5 points), Pitt bacteremia score ≥6 (4 points), Charlson index ≥2 (3 points) and source of BSI other 
than urinary or biliary tracts (3). b Variables with a univariate p ≤0.2 for mortality were included. The 
interactions studied are specified in Results. c Lack of multicollinearity in the multivariate model was assesed 
with the Variance inflation factor (VIF), which was ≤1.06 for all variables included (Supplementary Table S4). 
Abbreviations: OR, odds ratio; CI, confidence interval; OXA, oxacillinase; ESBL, extended-spectrum β-
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Table 3. INCREMENT-SOT-CPE score: assignment of scores based on the regression 




coefficients  (95% CI) 
Score 
INCREMENT-CPE score ≥8 2.62 (1.79-3.56) 8 
Cytomegalovirus disease in the previous 30 days 2.38 (0.58-4.34) 7 
Lymphocytes ≤ 600 mm3 1.24 (0.55-1.97) 4 
No source control 0.98 (0.17-1.83) 3 
Inappropriate empirical therapy 0.64 (-0.26-1.45) 2 
Interaction INCREMENT-CPE score ≥ 8 * Cytomegalovirus disease in the previous 30 daysa -2.39 [-4.90 - (-0.10)] -7 
Maximum score a  17 
 
a The negative interaction coefficient means that the effect of the combined action of two predictors is less than 
the sum of the individual effects.  Consequently, in our model, the maximum score in a patient with all risk 
factors would be 17 [INCREMENT-CPE score ≥8 (+8), CMV disease (+7), lymphopenia (+4), no source 
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Table 4. Adjusted Cox-regression analysis of the association of monotherapy versus 
combined therapy with 30-day all-cause mortality in the global cohort and in the 
different strata of risk, according to INCREMENT-SOT-CPE score. 
Patient group Variables  HR (95% CI) P value 




(N=165; 95 monotherapy, 70 combined) 
 
Monotherapy 3.68 (1.83-7.40) <0.001 
Propensity score 
b
 0.70 (0.12-4.19) 0.70 
High risk center 2.37 (1.37-4.10) 0.002 
INCREMENT-SOT-CPE score  
  Low risk Reference 
 High risk 5.13 (2.02-13.05) 0.001 
Very high risk 12.54 (5.45-28.87) <0.001 
Very high risk patients  Monotherapy 2.82 (1.13-7.06) 0.03 
(N=44; 30 monotherapy, 14 combined) Propensity score 
b
 0.48 (0.05-4.67) 0.53 
 
High risk center 1.23 (0.59-2.55) 0.58 
High risk patients  Monotherapy 9.93 (2.08-47.40) 0.004 
(N =47; 20 monotherapy, 27 combined ) Propensity score 
b
 0.41 (0.004-45.42) 0.71 
  High risk center 4.52 (1.38-14.79) 0.01 
Low risk patients  Monotherapy 1.69 (0.32-8.89) 0.54 
(N=74; 45 monotherapy, 29 combined ) Propensity score 
b
 2.76 (0.02-316.64) 0.68 
  High risk center 12.68 (1.50-107.49) 0.02 
 
a All variables exhibited a variance inflation factor (VIF) <1.7. The model showed an area under the receiver 
operating characteristic curve of 0.73. Antimicrobials administered as monotherapy or combined therapy, both 
in the global cohort and in the three INCREMENT-SOT-CPE mortality risk groups, and their related mortality 
are shown in Supplementary Table S8. b The variables used to calculate the propensity score for combination 
therapy were centre, period, age, sex, acquisition, hospital service, days from transplant to blood culture, type of 
SOT, SIRS, Charlson index, Pitt score, source of infection, lymphocytes count, source control, CMV disease, 
kidney disease, diabetes, dialysis (previous 30 days), myocardial infarct, type of enzyme, type of 
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Figure 2. Algorithm for clinical management of SOT patients with bloodstream infection due to carbapenemase-




*Risk factors for INCREMENT-SOT-CPE score: cytomegalovirus (CMV) disease during the last 30 days; 
lymphopenia (<600 lymphocytes/mm3) at BSI onset, no source control and inappropriate empirical therapy (in the 
first 3 days after blood culture).  
Abbreviations: CPE-BSI, bloodstream infection due to carbapenemase-producing Enterobacterales; SOT, solid 
organ transplant.  
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